The latest disclosed insider transactions at Elevance Health, Inc. (ELV) involve Ronald W. Penczek, who serves as the Chief Accounting Officer and Controller. On May 19, 2026, Mr. Penczek executed a sale of company common stock shares totaling $617,192. This disposition involved selling 1,531 shares at an average price of $403.13 per share.
The timing of this sale was notable as it followed the day's exercise of employee stock options. Mr. Penczek acquired a total of 1,531 shares through two distinct option exercises. The first acquisition involved 654 shares, executed at a price point of $271.27 per share. Separately, the second exercise accounted for 877 shares and was conducted at $311.48 per share. Collectively, these options were fully vested, generating an aggregate value of $450,578 across the two exercises, with prices ranging between $271.27 and $311.48.
The 1,531 shares sold were liquidated through multiple trades, all transacting at the consistent price of $403.13 per share. Following the execution of these sales, Mr. Penczek's remaining direct holding of Elevance Health common stock amounted to 4,109 shares. This current balance incorporates an additional 10.21 shares that were acquired on March 25, 2026, through participation in a dividend reinvestment plan.
Aside from the insider trading activity, Elevance Health has been the subject of several recent developments and strong analyst coverage following its first-quarter fiscal 2026 results. The company's performance metrics were highlighted by analysts across various financial institutions.
Specifically, Bernstein SocGen Group increased its price target for Elevance Health to $424, citing the quarter’s findings. These results indicated that adjusted earnings per share reached $12.58, which surpassed consensus estimates by 14%. Furthermore, the medical loss ratio was reported as slightly better than anticipated.
Mizuho also acted on the strong first-quarter performance and improved margin outlook, consequently raising its price target to $385 while maintaining an Outperform rating for Elevance Health. Complementing this sentiment, Deutsche Bank upgraded the company to a Buy rating and subsequently raised its price target to $498, attributing the positive shift partly to a stable managed care market outlook.
The broader context of the company's operations was also presented at its annual shareholder meeting. During this meeting, three directors were elected for three-year terms, and executive compensation packages received approval from shareholders. Additionally, Wolfe Research pointed out Elevance Health’s conservative Medicaid enrollment guidance for 2026, projecting a negative 8% change.
Current Market Context and Valuation
As of the reporting date, the stock is trading at $396.28. This current price level places it near its 52-week high of $412.96. The stock has demonstrated significant upward momentum over the past six months, posting a strong gain of 30%. From an analytical perspective, InvestingPro analysis suggests that Elevance Health may remain undervalued based on its Fair Value assessment. Furthermore, the company received a